Aerie Pharmaceuticals announced the appointment of Judith J. Robertson as Chief Commercial Officer, reporting to Thomas Mitro, Aerie President and Chief Operating Officer. Ms. Robertson will be responsible for leading the global commercialization of Aerie’s ophthalmology franchise, and joins Aerie from the Janssen Pharmaceutical Companies of Johnson & Johnson, where she has been the VP of Global Immunology, Ophthalmology and Global Analytics since 2013. Prior to Janssen, she was VP of Global Ophthalmology at Alcon, VP of Global Respiratory at Novartis, and President of Bristol Myers Squibb Canada.
In connection with the hiring of Ms. Robertson as Chief Commercial Officer, she received an award of 70,000 stock options and 18,000 shares of restricted stock awards. The stock options will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date; the restricted stock award will vest over a period of 4 years in four equal annual installments on each annual hire date anniversary. These awards were made outside of Aerie’s stockholder-approved equity incentive plan and was approved by the Company’s independent directors as an inducement material to Ms. Robertson’s entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.
“Judy brings a wealth of global commercialization and general management experience to Aerie as we progress into launch mode. We believe her proven skill set will serve us well as we prepare for commercialization of our product candidates,” Thomas Mitro, President and Chief Operating Officer at Aerie, said in a company news release.
Ms. Robertson added, “I am delighted to join Aerie as its first Chief Commercial Officer, and look forward to driving the exciting portfolio of Aerie product candidates to ultimate commercial success.”